CHICAGO - Cosmos Health Inc. (NASDAQ:COSM), a global healthcare group, announced the development of Cloudscreen 2.0, an advanced Artificial Intelligence (AI) platform designed to enhance drug repurposing. The initiative, unveiled today, follows the company's acquisition of the original Cloudscreen technology on January 23, 2024.
Cloudscreen 2.0 is set to build upon the capabilities of its predecessor by employing sophisticated AI and machine learning technologies. The platform aims to provide comprehensive drug-protein interaction predictions across the human proteome, incorporating extensive datasets that are over 100 times larger than those used previously. This expansion is expected to significantly improve the accuracy of predictions and confidence scores.
The new system will also utilize Graphics Processing Unit (GPU) cloud services for scaling up data processing. The integration of mutagenesis data and tools for disordered proteins, which play a role in various diseases, is intended to further the platform's predictive capabilities.
Greg Siokas, CEO of Cosmos Health, expressed optimism about the potential impact of Cloudscreen 2.0 on the company's research and development efforts, suggesting that successful outcomes could be transformative for Cosmos.
Cosmos Health, established in 2009 and headquartered in Nevada, owns a range of proprietary pharmaceutical and nutraceutical brands. The company manufactures and distributes healthcare products through its European Union-licensed subsidiary Cana Laboratories S.A. and operates in the telehealth sector with the acquisition of ZipDoctor, Inc.
The development of Cloudscreen 2.0 aligns with Cosmos Health's strategic focus on innovation in healthcare, particularly in the areas of obesity, diabetes, and cancer research. As the company continues to expand its global footprint, advancements like Cloudscreen 2.0 could play a critical role in its growth and product development.
This news is based on a press release statement from Cosmos Health Inc. and includes forward-looking statements subject to risks and uncertainties. Readers are encouraged to consider the risk factors outlined by the company in its SEC filings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.